Kristian Wachtell

List of Publications by Year
in descending order

258 papers	16,573 citations	22132 59 h-index	17580 121 g-index
296 all docs	296 docs citations	296 times ranked	14066 citing authors

#	Article	IF	Citations
1	Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. New England Journal of Medicine, 2008, 359, 1343-1356.	13.9	1,395
2	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. Journal of the American College of Cardiology, 2005, 45, 712-719.	1.2	796
3	Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension. JAMA - Journal of the American Medical Association, 2004, 292, 2350.	3.8	740
4	A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet, The, 2016, 388, 2665-2712.	6.3	670
5	Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Hypertension, 2005, 45, 198-202.	1.3	529
6	Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study. Annals of Internal Medicine, 2003, 139, 901.	2.0	468
7	Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol. Circulation, 2004, 110, 1456-1462.	1.6	435
8	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	6.3	414
9	Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. Journal of the American College of Cardiology, 2010, 55, 2299-2307.	1.2	374
10	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension, 2002, 20, 1879-1886.	0.3	345
11	Outcome of Patients With Low-Gradient â€œSevereâ€•Aortic Stenosis and Preserved Ejection Fraction. Circulation, 2011, 123, 887-895.	1.6	304
12	Short- and Long-Term Cause of Death inÂPatients Treated With Primary PCI forÂSTEMI. Journal of the American College of Cardiology, 2014, 64, 2101-2108.	1.2	301
13	Risk prediction is improved by adding markers of subclinical organ damage to SCORE. European Heart Journal, 2010, 31, 883-891.	1.0	255
14	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation. Journal of the American College of Cardiology, 2005, 45, 705-711.	1.2	250
15	Regression of Electrocardiographic Left Ventricular Hypertrophy and Decreased Incidence of New-Onset Atrial Fibrillation in Patients With Hypertension. JAMA - Journal of the American Medical Association, 2006, 296, 1242.	3.8	238
16	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
17	Impact of Different Partition Values on Prevalences of Left Ventricular Hypertrophy and Concentric Geometry in a Large Hypertensive Population. Hypertension, 2000, 35, 6-12.	1.3	216
18	Correlates of Left Atrial Size in Hypertensive Patients With Left Ventricular Hypertrophy. Hypertension, 2002, 39, 739-743.	1.3	213

#	Article	IF	Citations
19	Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death. Circulation, 2007, 116, 700-705.	1.6	203
20	Left Atrial Size and Risk of Major Cardiovascular Events During Antihypertensive Treatment. Hypertension, 2007, 49, 311-316.	1.3	202
21	Low-Flow Aortic Stenosis in Asymptomatic Patients. JACC: Cardiovascular Imaging, 2009, 2, 390-399.	2.3	192
22	Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment. Circulation, 2002, 105, 1071-1076.	1.6	174
23	Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. American Heart Journal, 2019, 214, 60-68.	1.2	160
24	Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study)âˆ—âˆ—See Appendix for the list of LIFE investigators.. American Journal of Cardiology, 2000, 85, 466-472.	0.7	153
25	N-Terminal Pro Brain Natriuretic Peptide Is Inversely Related to Metabolic Cardiovascular Risk Factors and the Metabolic Syndrome. Hypertension, 2005, 46, 660-666.	1.3	152
26	Design and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. American Journal of Cardiology, 2007, 99, 970-973.	0.7	143
27	Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Journal of Hypertension, 2002, 20, 405-412.	0.3	139
28	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	6.3	133
29	Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). European Journal of Echocardiography, 2008, 9, 809-815.	2.3	132
30	Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. American Heart Journal, 2002, 143, 319-326.	1.2	130
31	N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. European Heart Journal, 2007, 28, 1374-1381.	1.0	122
32	Prognostic Value of Energy Loss Index in Asymptomatic Aortic Stenosis. Circulation, 2013, 127, 1149-1156.	1.6	117
33	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of Hypertension, 2004, 22, 1805-1811.	0.3	114
34	Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest. Resuscitation, 2013, 84, 162-167.	1.3	110
35	Gender Differences in Left Ventricular Structure and Function During Antihypertensive Treatment. Hypertension, 2008, 51, 1109-1114.	1.3	109
36	Echocardiographic Left Ventricular Geometry in Hypertensive Patients with Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study. Blood Pressure, 2001, 10, 74-82.	0.7	105

#	Article	IF	Citations
37	Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study. Diabetes Care, 2006, 29, 595-600.	4.3	105
38	Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. American Heart Journal, 1999, 137, 1062-1069.	1.2	104
39	Impact of Pressure Recovery on Echocardiographic Assessment of Asymptomatic Aortic Stenosis: A SEAS Substudy. JACC: Cardiovascular Imaging, 2010, 3, 555-562.	2.3	103
40	Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study.. Journal of Hypertension, 2001, 19, 1883-1891.	0.3	100
41	Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol. Hypertension, 2005, 45, 46-52.	1.3	90
42	Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet, The, 2003, 362, 619-620.	6.3	87
43	Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	0.7	87
44	Four-Group Classification of Left Ventricular Hypertrophy Based on Ventricular Concentricity and Dilatation Identifies a Low-Risk Subset of Eccentric Hypertrophy in Hypertensive Patients. Circulation: Cardiovascular Imaging, 2014, 7, 422-429.	1.3	87
45	suPAR: A New Biomarker for Cardiovascular Disease?. Canadian Journal of Cardiology, 2015, 31, 1293-1302.	0.8	84
46	Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study. Journal of Hypertension, 2006, 24, 775-781.	0.3	80
47	N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy. Journal of Hypertension, 2004, 22, 1597-1604.	0.3	78
48	Change in Systolic Left Ventricular Performance After 3 Years of Antihypertensive Treatment. Circulation, 2002, 106, 227-232.	1.6	77
49	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. Journal of Hypertension, 2002, 20, 1445-1450.	0.3	75
50	Pulse pressure/stroke index and left ventricular geometry and function. Journal of Hypertension, 2003, 21, 781-787.	0.3	71
51	Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. American Heart Journal, 2002, 144, 1057-1064.	1.2	70
52	Factors Influencing Left Ventricular Structure and Stress-Corrected Systolic Function in Men and Women With Asymptomatic Aortic Valve Stenosis (a SEAS Substudy). American Journal of Cardiology, 2008, 101, 510-515.	0.7	70
53	Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE study). American Journal of Cardiology, 2001, 87, 54-60.	0.7	69
54	Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study. American Heart Journal, 2001, 141, 784-791.	1.2	68

#	Article	IF	Citations
55	Heart Rate Versus Heart Rate Variability in Risk Prediction after Myocardial Infarction. Journal of Cardiovascular Electrophysiology, 2003, 14, 168-173.	0.8	67
56	Left ventricular wall stresses and wall stressâ€“massâ€“heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy. Journal of Hypertension, 2000, 18, 1129-1138.	0.3	66
57	Clinical Implications of Electrocardiographic Left Ventricular Strain and Hypertrophy in Asymptomatic Patients With Aortic Stenosis. Circulation, 2012, 125, 346-353.	1.6	65
58	Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). American Journal of Cardiology, 2002, 89, 337-341.	0.7	63
59	Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients. Hypertension, 2015, 66, 368-373.	1.3	63
60	Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 243-251.	2.1	61
61	Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension, 2020, 75, 23-32.	1.3	61
62	Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. Journal of Hypertension, 2012, 30, 1928-1936.	0.3	60
63	In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Pressure, 2010, 19, 169-175.	0.7	59
64	Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy. Hypertension, 2012, 60, 347-353.	1.3	59
65	Newâ€Onset Atrial Fibrillation is Associated With Cardiovascular Events Leading to Death in a First Time Myocardial Infarction Population of 89Â703 Patients With Longâ€Term Followâ€Up: A Nationwide Study. Journal of the American Heart Association, 2014, 3, e000382.	1.6	59
66	Observed and Predicted Reduction of Ischemic Cardiovascular Events in the Simvastatin and Ezetimibe in Aortic Stenosis Trial. American Journal of Cardiology, 2010, 105, 1802-1808.	0.7	58
67	Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. American Heart Journal, 2002, 144, 530-537.	1.2	55
68	N-terminal pro brain natriuretic peptide in arterial hypertension-a marker for left ventricular dimensions and prognosis. European Journal of Heart Failure, 2004, 6, 313-317.	2.9	55
69	Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. Journal of Human Hypertension, 2004, 18, 453-459.	1.0	54
70	Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 337-343.	2.1	54
71	Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. Journal of Hypertension, 2005, 23, 891-898.	0.3	53
72	QT dynamics in risk stratification after myocardial infarction. Heart Rhythm, 2005, 2, 357-364.	0.3	52

#	Article	IF	Citations
73	Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). Journal of Hypertension, 2010, 28, 377-383.	0.3	52
74	Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis. Heart, 2014, 100, 28-33.	1.2	51
75	Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. Journal of Human Hypertension, 2004, 18, 403-409.	1.0	49
76	Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Pressure, 2005, 14, 177-183.	0.7	49
77	Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. Journal of Human Hypertension, 2007, 21, 625-632.	1.0	48
78	Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage. Journal of Hypertension, 2015, 33, 2422-2430.	0.3	47
79	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545.	0.3	47
80	Left Atrial Volume in Patients With Asymptomatic Aortic Valve Stenosis (the Simvastatin and Ezetimibe) Tj ETQq0 0 0 rgBT /Overlock 10	0.7	46
81	Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: The LIFE Study. Journal of Hypertension, 2001, 19, 127-134.	0.3	43
82	Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy. Circulation, 2005, 111, 1924-1931.	1.6	43
83	Prognostic Significance of Left Ventricular Diastolic Dysfunction in Patients With Left Ventricular Hypertrophy and Systemic Hypertension (the LIFE Study). American Journal of Cardiology, 2010, 106, 999-1005.	0.7	42
84	Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis study. International Journal of Cardiology, 2013, 166, 72-76.	0.8	42
85	Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF. Heart, 2014, 100, 1946-1953.	1.2	41
86	Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. Journal of Hypertension, 2009, 27, 2351-2357.	0.3	39
87	In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. Journal of Hypertension, 2010, 28, 1541-1546.	0.3	39
88	Adipocytokines, C-Reactive Protein, and Cardiovascular Disease: A Population-Based Prospective Study. PLoS ONE, 2015, 10, e0128987.	1.1	39
89	Novel Trial Designs: Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction in Scandinavia (TASTE) Trial. Current Cardiology Reports, 2016, 18, 11.	1.3	38
90	Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. American Heart Journal, 2003, 145, 919-925.	1.2	37

#	Article	IF	Citations
91	Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis. Circulation, 2016, 134, 455-468.	1.6	37
92	A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Journal of Human Hypertension, 2002, 16, 591-595.	1.0	36
93	Echocardiographic Wall Motion Abnormalities in Hypertensive Patients With Electrocardiographic Left Ventricular Hypertrophy. Hypertension, 2003, 41, 75-82.	1.3	36
94	Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension: a LIFE substudy. Journal of Human Hypertension, 2004, 18, 445-452.	1.0	36
95	Positron Emission Tomographic Evaluation of Regulation of Myocardial Perfusion in Physiological (Elite Athletes) and Pathological (Systemic Hypertension) Left Ventricular Hypertrophy. American Journal of Cardiology, 2005, 96, 1692-1698.	0.7	35
96	Asymmetric septal hypertrophy â€“ a marker of hypertension in aortic stenosis (a SEAS substudy). Blood Pressure, 2010, 19, 140-144.	0.7	35
97	Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. Journal of Hypertension, 2005, 23, 1083-1090.	0.3	34
98	N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. Journal of Hypertension, 2006, 24, 1531-1539.	0.3	34
99	Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. Journal of Human Hypertension, 2005, 19, 301-307.	1.0	33
100	High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. Journal of Hypertension, 2006, 24, 655-661.	0.3	33
101	Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. Journal of Hypertension, 2008, 26, 26-34.	0.3	33
102	Impact of QRS Duration and Morphology on the Risk of Sudden Cardiac Death in Asymptomatic Patients With Aortic Stenosis. Journal of the American College of Cardiology, 2012, 59, 1142-1149.	1.2	33
103	Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Journal of Hypertension, 2000, 18, 75-81.	0.3	32
104	Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: The simvastatin and ezetimibe in aortic stenosis study. International Journal of Cardiology, 2013, 168, 2322-2327.	0.8	32
105	Reninâ€“angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. International Journal of Cardiology, 2014, 175, 492-498.	0.8	31
106	Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Kidney International, 2004, 66, S56-S58.	2.6	30
107	Impact of Baseline Severity of Aortic Valve Stenosis on Effect of Intensive Lipid Lowering Therapy (from the SEAS Study). American Journal of Cardiology, 2010, 106, 1634-1639.	0.7	30
108	Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 634-640.	1.1	29

#	Article	IF	Citations
109	Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?. Journal of Hypertension, 2009, 27, 1165-1171.	0.3	29
110	Natural History of Mild and of Moderate Aortic Stenosisâ€"New Insights From a Large Prospective European Study. Current Problems in Cardiology, 2013, 38, 365-409.	1.1	28
111	Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). American Journal of Cardiology, 2004, 94, 1076-1080.	0.7	27
112	Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk. Hypertension, 2005, 46, 492-499.	1.3	27
113	Differences in Cardiovascular Risk Profile Between Electrocardiographic Hypertrophy Versus Strain in Asymptomatic Patients With Aortic Stenosis (from SEAS Data). American Journal of Cardiology, 2011, 108, 541-547.	0.7	27
114	Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). Blood Pressure, 2014, 23, 206-212.	0.7	27
115	Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 739-745.	0.7	27
116	Serum Uric Acid Is Associated With New-Onset Diabetes in Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Study. American Journal of Hypertension, 2010, 23, 845-851.	1.0	26
117	Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study. American Journal of Hypertension, 2012, 25, 1101-1109.	1.0	26
118	Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 122-129.	1.1	26
119	Overweight, adipocytokines and hypertension. Journal of Hypertension, 2014, 32, 1488-1494.	0.3	26
120	Aortic Valve Sclerosis and Albuminuria Predict Cardiovascular Events Independently in HypertensionA Losartan Intervention for Endpoint-reduction in Hypertension (LIFE) Substudy. American Journal of Hypertension, 2005, 18, 1430-1436.	1.0	25
121	Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevation myocardial infarction after revascularization with either fibrinolysis or primary angioplasty. European Heart Journal, 2007, 28, 407-414.	1.0	25
122	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. Journal of Hypertension, 2008, 26, 1244-1249.	0.3	25
123	Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. Journal of Hypertension, 2010, 28, 1534-1540.	0.3	25
124	The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions. International Journal of Cardiology, 2013, 167, 624-630.	0.8	25
125	Mitral Annular Calcification and Incident Ischemic Stroke in Treated Hypertensive Patients: The LIFE study.. American Journal of Hypertension, 2013, 26, 567-573.	1.0	25
126	Stroke in Patients With Aortic Stenosis. Stroke, 2014, 45, 1939-1946.	1.0	25

#	Article	IF	Citations
127	Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from) Tj ETQq1 1 0.784314 rgBT /Over 1840-1844.	0.7	25
128	Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. Journal of Human Hypertension, 2004, 18, 411-416.	1.0	24
129	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. American Heart Journal, 2004, 148, 538-544.	1.2	24
130	Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension, 2009, 27, 567-574.	0.3	24
131	Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. American Journal of Hypertension, 2012, 25, 678-683.	1.0	24
132	Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction. International Journal of Cardiology, 2016, 203, 697-701.	0.8	24
133	Antihypertensive Treatment With Î²â€Blockade in Patients With Asymptomatic Aortic Stenosis and Association With Cardiovascular Events. Journal of the American Heart Association, 2017, 6, .	1.6	24
134	Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension, 2004, 18, 397-402.	1.0	23
135	Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 306-312.	1.1	23
136	The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. Journal of Atrial Fibrillation, 2013, 5, 789.	0.5	23
137	Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. Journal of Cardiac Failure, 2002, 8, 8-14.	0.7	22
138	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. Journal of Hypertension, 2007, 25, 871-876.	0.3	22
139	A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis. Heart, 2012, 98, 377-383.	1.2	22
140	Do Î²-Blockers Cause Depression?. Hypertension, 2021, 77, 1539-1548.	1.3	22
141	Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension, 2006, 24, 2079-2084.	0.3	21
142	Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Journal of Hypertension, 2007, 25, 1079-1085.	0.3	21
143	Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 242-248.	3.1	21
144	Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). Journal of Human Hypertension, 2004, 18, 417-422.	1.0	20

#	Article	IF	Citations
145	Mitral E Wave Deceleration Time to Peak E Velocity Ratio and Cardiovascular Outcome in Hypertensive Patients During Antihypertensive Treatment (from the LIFE Echo-Substudy). American Journal of Cardiology, 2009, 104, 1098-1104.	0.7	20
146	Left Ventricular Wall Stressâ€“Massâ€“Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients. Hypertension, 2015, 66, 945-953.	1.3	20
147	Combination of the Electrocardiographic Strain Pattern and Albuminuria for the Prediction of New-onset Heart Failure in Hypertensive Patients: The LIFE Study. American Journal of Hypertension, 2008, 21, 273-279.	1.0	19
148	The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 507-513.	1.0	19
149	Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: The LIFE study. Journal of Human Hypertension, 2011, 25, 178-185.	1.0	19
150	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 2014, 21, 434-441.	0.8	19
151	Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE study. American Journal of Hypertension, 2001, 14, 768-774.	1.0	18
152	Adjusting parameters of aortic valve stenosis severity by body size. Heart, 2014, 100, 1024-1030.	1.2	18
153	24-h Ambulatory blood pressure in patients with ECG-determined left ventricular hypertrophy: left ventricular geometry and urinary albumin excretionâ€”a LIFE substudy. Journal of Human Hypertension, 2004, 18, 391-396.	1.0	17
154	Beat-to-beat QT dynamics in paroxysmal atrial fibrillation. Heart Rhythm, 2006, 3, 660-664.	0.3	17
155	Aortic root geometry in aortic stenosis patients (a SEAS substudy). European Journal of Echocardiography, 2011, 12, 585-590.	2.3	17
156	Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. American Heart Journal, 2012, 163, 690-696.	1.2	17
157	Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients. Journal of Hypertension, 2013, 31, 2060-2068.	0.3	17
158	Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Journal of Hypertension, 2014, 32, 667-672.	0.3	17
159	Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study. European Journal of Preventive Cardiology, 2014, 21, 330-338.	0.8	17
160	Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study. Diabetic Medicine, 2005, 22, 1005-1011.	1.2	16
161	Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension, 2008, 26, 1472-1476.	0.3	16
162	Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. American Journal of Hypertension, 2002, 15, 398-404.	1.0	15

#	Article	IF	Citations
163	Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). American Journal of Cardiology, 2002, 89, 399-402.	0.7	15
164	Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension, 2004, 18, 431-436.	1.0	15
165	Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. Journal of Hypertension, 2015, 33, 1480-1486.	0.3	15
166	Worsening diastolic function is associated with elevated fasting plasma glucose and increased left ventricular mass in a supra-additive fashion in an elderly, healthy, Swedish population. International Journal of Cardiology, 2015, 184, 466-472.	0.8	14
167	Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study. Blood Pressure, 2017, 26, 150-155.	0.7	14
168	Maximal exercise capacity is related to cardiovascular structure in patients with longstanding hypertension. a LIFE substudy. American Journal of Hypertension, 2001, 14, 1205-1210.	1.0	13
169	Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy. Journal of Human Hypertension, 2003, 17, 305-311.	1.0	13
170	Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension, 2004, 18, 423-430.	1.0	13
171	Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: The LIFE Study. Blood Pressure, 2012, 21, 6-11.	0.7	13
172	Extracellular Matrix Biomarker, Fibulin-1, Is Closely Related to NT-proBNP and Soluble Urokinase Plasminogen Activator Receptor in Patients with Aortic Valve Stenosis (The SEAS Study). PLoS ONE, 2014, 9, e101522.	1.1	13
173	Sudden cardiac death in asymptomatic patients with aortic stenosis. Heart, 2020, 106, 1646-1650.	1.2	13
174	Endothelial dysfunction in resistance arteries is related to high blood pressure and circulating low density lipoproteins in previously treated hypertension. American Journal of Hypertension, 2001, 14, 861-867.	1.0	12
175	Losartan versus atenolol on 24â€hour ambulatory blood pressure. A LIFE substudy. Blood Pressure, 2007, 16, 392-397.	0.7	12
176	New risk markers may change the HeartScore risk classification significantly in one-fifth of the population. Journal of Human Hypertension, 2009, 23, 105-112.	1.0	12
177	In-treatment stroke volume predicts cardiovascular risk in hypertension. Journal of Hypertension, 2011, 29, 1508-1514.	0.3	12
178	Five-year weight changes associate with blood pressure alterations independent of changes in serum insulin. Journal of Hypertension, 2014, 32, 2231-2237.	0.3	12
179	Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis. American Journal of Cardiology, 2019, 124, 1736-1740.	0.7	12
180	Association of Hemoglobin Delivery With Left Ventricular Structure and Function in Hypertensive Patients. Hypertension, 2006, 47, 868-873.	1.3	11

#	Article	IF	Citations
181	Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study. American Heart Journal, 2009, 157, 177-184.	1.2	11
182	Urine Albumin/Creatinine Ratio, High Sensitivity C-Reactive Protein and N-Terminal Pro Brain Natriuretic Peptide - Three New Cardiovascular Risk Markers - Do They Improve Risk Prediction and Influence Treatment?. Current Vascular Pharmacology, 2010, 8, 134-139.	0.8	11
183	Left Atrial Volume as Predictor of Valve Replacement and Cardiovascular Events in Patients with Asymptomatic Mild to Moderate Aortic Stenosis. Echocardiography, 2013, 30, 1008-1014.	0.3	11
184	Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: The SEAS study. International Journal of Cardiology, 2015, 180, 122-128.	0.8	11
185	Increased hsCRP is associated with higher risk of aortic valve replacement in patients with aortic stenosis. Scandinavian Cardiovascular Journal, 2016, 50, 138-145.	0.4	11
186	SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis. Canadian Journal of Cardiology, 2016, 32, 1462-1469.	0.8	11
187	SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis. Open Heart, 2018, 5, e000743.	0.9	11
188	Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Pressure, 2019, 28, 317-326.	0.7	11
189	Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. American Journal of Hypertension, 2003, 16, 180-186.	1.0	10
190	Does longâ€term losartanâ€vs atenololâ€based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. Blood Pressure, 2006, 15, 198-206.	0.7	10
191	Contrasting Hemodynamic Mechanisms of Losartan- vs. Atenolol-Based Antihypertensive Treatment: A LIFE Study. American Journal of Hypertension, 2012, 25, 1017-1023.	1.0	10
192	Higher Serum Concentrations of N-Terminal Pro-B-Type Natriuretic Peptide Associate with Prevalent Hypertension whereas Lower Associate with Incident Hypertension. PLoS ONE, 2015, 10, e0117864.	1.1	10
193	Clinical impact of â€˜in-treatmentâ€™ wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension, 2008, 26, 806-812.	0.3	9
194	Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). Blood Pressure, 2009, 18, 180-186.	0.7	9
195	Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients. Journal of Hypertension, 2012, 30, 1252-1259.	0.3	9
196	SALTIREâ€“RAAVE: targeting calcific aortic valve disease LDL-density-radius theory. Expert Review of Cardiovascular Therapy, 2015, 13, 355-367.	0.6	9
197	Pro-coagulant activity during exercise testing in patients with coronary artery disease. Thrombosis Journal, 2017, 15, 3.	0.9	9
198	Left Ventricular Hypertrophy is Associated with Reduced Vasodilatory Capacity in the Brachial Artery in Patients with Longstanding Hypertension. A LIFE Substudy. Blood Pressure, 2002, 11, 285-292.	0.7	8

#	Article	IF	Citations
199	Is it time to change the definition of normal urinary albumin excretion?. Nature Clinical Practice Nephrology, 2008, 4, 650-651.	2.0	8
200	Left ventricular systolic performance in asymptomatic aortic stenosis. Country Review Ukraine, 2008, 10, E16-E22.	0.8	8
201	Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?. Journal of Hypertension, 2012, 30, 513-521.	0.3	8
202	Structural and Functional Cardiac Changes Are Target Organ Damage That Increases Risk of Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 2014-2015.	1.2	8
203	Usefulness of the Electrocardiogram in Predicting Cardiovascular Mortality in Asymptomatic Adults With Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). American Journal of Cardiology, 2014, 114, 751-756.	0.7	8
204	Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients. Journal of Hypertension, 2014, 32, 2472-2478.	0.3	8
205	Arterial Stiffness Predicts Incident Atrial Fibrillation in the Framingham Heart Study. Hypertension, 2016, 68, 555-557.	1.3	8
206	High-sensitive cardiac Troponin T and exercise stress test for evaluation of angiographically significant coronary disease. International Journal of Cardiology, 2019, 287, 1-6.	0.8	8
207	Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? a LIFE substudy. Journal of Human Hypertension, 2004, 18, 437-443.	1.0	7
208	Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). American Journal of Cardiology, 2005, 95, 280-283.	0.7	7
209	Electrocardiographic and Echocardiographic Detection of Myocardial Infarction in Patients with Left-Ventricular HypertrophyThe LIFE Study. American Journal of Hypertension, 2007, 20, 771-776.	1.0	7
210	Change in Pulse Pressure/Stroke Index in Response to Sustained Blood Pressure Reduction and Its Impact on Left Ventricular Mass and Geometry Changes: the Life Study. American Journal of Hypertension, 2008, 21, 701-707.	1.0	7
211	Atrial Fibrillation, Maybe it Is Not So Lone?âŽâŽEditorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2009, 53, 30-31.	1.2	7
212	High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy. Open Heart, 2015, 2, e000152.	0.9	7
213	Acute myocardial infarction and lesion location in the left circumflex artery: importance of coronary artery dominance. EuroIntervention, 2016, 12, 441-448.	1.4	7
214	Longâ€Term Effects of a Losartanâ€Compared With an Atenololâ€Based Treatment Regimen on Carotid Artery Plaque Development in Hypertensive Patients With Left Ventricular Hypertrophy: ICARUS, a LIFE Substudy. Journal of Clinical Hypertension, 2006, 8, 169-173.	1.0	6
215	Racial Differences in Incident Atrial Fibrillation Among Hypertensive Patients During Antihypertensive Therapy. American Journal of Hypertension, 2014, 27, 966-972.	1.0	6
216	Effect of simvastatin and ezetimibe on suPAR levels and outcomes. Atherosclerosis, 2018, 272, 129-136.	0.4	6

#	Article	IF	Citations
217	Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial. American Journal of Hypertension, 2002, 15, A15.	1.0	5
218	Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. Current Cardiology Reports, 2006, 8, 356-364.	1.3	5
219	Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. Journal of Human Hypertension, 2004, 18, 375-380.	1.0	4
220	Prevalence and Prognostic Implications of ST-Segment Deviations from Ambulatory Holter Monitoring After ST-Segment Elevation Myocardial Infarction Treated With Either Fibrinolysis or Primary Percutaneous Coronary Intervention (a Danish Trial in Acute Myocardial Infarction-2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 612 T	0.7	4
221	Pre-Discharge Exercise Test for Evaluation of Patients with Complete or Incomplete Revascularization following Primary Percutaneous Coronary Intervention: A DANAMI-2 Sub-Study. Cardiology, 2008, 109, 163-171.	0.6	4
222	Review: Does lowering cholesterol have an impact on the progression of aortic stenosis?. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 277-286.	1.0	4
223	Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. Journal of Hypertension, 2011, 29, 997-1004.	0.3	4
224	Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis. JAMA Cardiology, 2022, 7, 435.	3.0	4
225	Impact of the metabolic syndrome on the predictive values of new risk markers in the general population. Journal of Human Hypertension, 2008, 22, 634-640.	1.0	3
226	Atrial fibrillation is target organ damage caused by an impaired haemodynamic state. Heart, 2018, 104, 1234-1235.	1.2	3
227	The effect of angiotensin receptor blockers for preventing atrial fibrillation. Current Hypertension Reports, 2007, 9, 278-283.	1.5	2
228	Prevention of congestive heart failure in high risk patients. European Heart Journal, 2008, 30, 638-639.	1.0	2
229	Impaired left ventricular systolic function in patients with left ventricular hypertrophy. Journal of Hypertension, 2011, 29, 2068-2069.	0.3	2
230	Leisure-time physical inactivity and risk of myocardial infarction and all-cause mortality: A caseâ€“control study. International Journal of Cardiology, 2014, 177, 599-600.	0.8	2
231	An age-old test in old age. Journal of Hypertension, 2016, 34, 2145-2146.	0.3	2
232	On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Blood Pressure, 2020, 29, 319-326.	0.7	2
233	Hypertensive Heart Disease â€“ Diagnosis, Prognostic Value and Changes During Antihypertensive Treatment, Left Ventricular Structure and Function. European Cardiology Review, 2010, 6, 23.	0.7	2
234	Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study. Exploration of Medicine, 0, , 128-138.	1.5	2

#	Article	IF	Citations
235	Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophyâ€“Application of A New Multivariate Predictive Model. The Life Study. Reviews in Cardiovascular Medicine, 2022, 23, 095.	0.5	2
236	Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of Medicine, 0, , 139-148.	1.5	2
237	Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of Medicine, 0, , 160-172.	1.5	2
238	The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. Journal of Human Hypertension, 2006, 20, 460-464.	1.0	1
239	Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. Blood Pressure, 2010, 19, 145-151.	0.7	1
240	Response to Letters Regarding Article, â€œOutcome of Patients With Low-Gradient â€œSevereâ€•Aortic Stenosis and Preserved Ejection Fractionâ€• Circulation, 2011, 124, .	1.6	1
241	Global systolic load, left ventricular hypertrophy, and atrial fibrillation. American Heart Journal, 2012, 164, e13.	1.2	1
242	Regression of target organ damage. Journal of Hypertension, 2013, 31, 1535-1536.	0.3	1
243	What is not to like about large national or international registries and databases?. International Journal of Cardiology, 2018, 262, 117-118.	0.8	1
244	Albuminuria and Mortality in Hypertension. Annals of Internal Medicine, 2004, 141, 245.	2.0	1
245	Atrial Fibrillation and Reninâ€“Angiotensin System Blockade in Hypertension. European Cardiology Review, 2009, 5, 63.	0.7	1
246	Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of Medicine, 0, , 149-159.	1.5	1
247	The sweet development and progression of aortic stenosis. Heart, 0, , heartjnl-2022-321331.	1.2	1
248	Does losartan treated patients with albuminuria have better cardiovascular outcome than those treated with atenolol? The LIFE study. American Journal of Hypertension, 2002, 15, A21.	1.0	0
249	The effect of losartan versus atenolol on carotid atherosclerosis in the common carotid arteries in hypertension. Icarus, a life substudy. American Journal of Hypertension, 2004, 17, S111.	1.0	0
250	When to Operate: Severe Aortic Stenosis Is Still a Clinical Enigma. American Journal of Cardiology, 2013, 112, 1510-1511.	0.7	0
251	IMPORTANCE OF AORTIC VALVE REPLACEMENT ON STROKE VOLUME INDEX IN LOW FLOW SEVERE AORTIC VALVE STENOSIS. Journal of the American College of Cardiology, 2014, 63, A2000.	1.2	0
252	STROKE IN PATIENTS WITH AORTIC STENOSIS: THE SIMVASTATIN AND EZETIMIBE IN AORTIC STENOSIS STUDY. Journal of the American College of Cardiology, 2014, 63, A2017.	1.2	0

#	Article	IF	Citations
253	Consensus document on hypertension and cardiac arrhythmias. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 251-252.	1.4	0
254	Association of left bundle branch block with new onset abnormal wall motion in treated hypertensive patients with left ventricle hypertrophy: the LIFE Echo Sub-study. Blood Pressure, 2019, 28, 84-92.	0.7	0
255	Frequency and Impact of Hyponatremia on All-Cause Mortality in Patients With Aortic Stenosis. American Journal of Cardiology, 2021, 141, 93-97.	0.7	0
256	DOES HORMONES REPLACEMENT THERAPY IN WOMEN INFLUENCE THEIR BENEFIT OF LOSARTAN-TREATMENT IN THE LIFE STUDY?. Journal of Hypertension, 2004, 22, S114.	0.3	0
257	The Electrocardiogram as a Risk Predictor in Asymptomatic Aortic Stenosis. , 2013, , 35-45.		0
258	Exercise-induced change in circulating NT-proBNP could not distinguish between patients with and without coronary artery disease: the CADENCE study. Scandinavian Cardiovascular Journal, 2022, 56, 107-113.	0.4	0